Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50.
As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine,
Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies.
Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.
Education & Training
Senior Fellow, University of Washington, Seattle WA, 2002-2007
Research Associate, Albert Einstein College of Medicine, Bronx NY, 2001-2002
PhD, Kyoto University, Kyoto, Japan, 2001
MS, Kyoto University, Kyoto, Japan, 1997
College, Kyoto University, Kyoto, Japan, 1995